Drugs / Olgotrelvir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05523739 | Sep → Dec 2022 | COVID-19 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05364840 | Jun → Oct 2022 | COVID-19 | Sorrento Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olgotrelvir | “Olgotrelvir (STI-1558) is designed as a next-generation antiviral targeting the SARS-CoV-2 main protease (Mpro), an essential enzyme for SARS-CoV-2 replication, and human...” PMID 38181791 ↗ Jan 2024 |
| Known as | STI-1558 | “Olgotrelvir (STI-1558) is designed as a next-generation antiviral targeting the SARS-CoV-2 main protease (Mpro), an essential enzyme for SARS-CoV-2 replication, and human...” PMID 38181791 ↗ Jan 2024 |
| Action | Inhibit | “Olgotrelvir is an oral inhibitor targeting Mpro and CTSL” PMID 38181791 ↗ Jan 2024 |
| Modality | Small molecule | “An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).” NCT05523739 ↗ |
| Route | Oral | “An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).” NCT05523739 ↗ |
| Target | CTSL | “targeting the SARS-CoV-2 main protease (Mpro), an essential enzyme for SARS-CoV-2 replication, and human cathepsin L (CTSL)” PMID 38181791 ↗ Jan 2024 |